Going Through the Motions
If the pharma industry got a dollar for every time it talked about improving relationships with payers, it probably wouldn ’t have a grave pricing challenge on its hands.Looking at it rationally, there is a clear win-win from greater harmony – pharma understands in advance the concerns of payers and can adjust its strategy to ensure effective market access, while payers get a heads-up on drugs are coming through and what impact they will have, and can plan budgets ahead.Yet, the reality is somewhat different. Collaboration – the word de jour for pharma in this decade – does not come easily, and many...
Source: EyeForPharma - August 6, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Navigating the Chaos
" If you ’re not confused, you’re not paying attention.”This quote from best-selling author and business guru Tom Peters ’Thriving On Chaos could have been written for pharma right now.Megatrends disrupt the landscape, while political and economic uncertainties make predicting the future a fool ’s game. Chaos is everywhere, not least in patient access.How companies respond may well have a lot to do with that eternal question – is the glass half-full or half-empty?“I like the uncertainty that chaos brings in filling up that glass,” says John A. Bardi, VP, Public Affairs a...
Source: EyeForPharma - August 6, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Flying The Flag For Patients
Patient-centricity rose like a phoenix from the ashes of the blockbuster era. After decades of focus almost entirely on the prescription pads of physicians (we even supplied the pens!), it was only a handful of years ago that pharma companies felt the winds of change on their faces. Many tacked to catch those winds in their sails.However, turning a vessel as large and unwieldy as a multinational corporation is no easy task. Getting sales reps, marketers, medical affairs, health economists, clinicians, scientists and senior managers to stop asking, What do HCPs need? and start asking, What do patients need? was always going...
Source: EyeForPharma - August 2, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

Seeking the Holy Grail of RWE
Billion-dollar acquisitions tend to make a lot of noise. Markets react, competitors get jittery and share prices can spike or tumble.When Roche bought Flatiron Health, a tech platform that captures and synthesizes structured and unstructured oncology data, for $1.9 billion back in February, it sent tremors throughout the healthcare industry.The ripple effect cannot be chalked up to corporate muscle-flexing however. The deal sent an unequivocal message that the time has come to establish a regulatory-grade standard for real-world evidence.Commenting on the tie-up, Roche ’s CEO said, “This is an important step in...
Source: EyeForPharma - August 2, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Achieve value-based contracting - true partnerships with patients for improved data quality and outcomes
Channels: Access and EvidenceImage: URL: https://www.eyeforpharma.com/rwe/webinar3/?partner=efp-WebsiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - July 31, 2018 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Five Reasons Why Clinical Trials Fail And What Pharma is Doing To Fix It
If echo chambers, polarizing politics and solipsism sums up the world in 2018, the art of listening has become gold dust.The pharma industry appears to be bucking the trend however. When it comes to the patient voice, companies are becoming all ears, with patient insights driving internal decisions across the board.We decided to put this proposition to the test.One of pharma ’s perennial thorns is clinical trial recruitment. 86% of clinical trials do not reach recruitment targets within their specified time periods. Patients clearly have their grievances but are pharma companies truly listening? More importantly, are...
Source: EyeForPharma - July 27, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Six Ways Artificial Intelligence Is Impacting Patients
It ’s difficult to open a newspaper nowadays without seeing an article about artificial intelligence. These column-inches spark our imaginations with heady visions of possible futures and crease our brows with concern in equal measure. But one thing you cannot escape is that AI is here now and it’s only going to become more pervasive.While fear of an unknown technology is understandable, in many ways it does a disservice to the incredible impact that AI is already having on the world around us. In the healthcare space alone, it is offering ways to fundamentally rethink clinical practice, speeding up diagnosis, ...
Source: EyeForPharma - July 24, 2018 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Tackling Stigma
Sadly, stigma around health conditions remains a part of many patients ’ lives. Many will not disclose a diagnosis for fear of being judged by peers, employers, health professionals, colleagues and wider society. In fact, there is clear evidence that such negative societal attitudes impact health outcomes, resulting in diagnosis delays and impaired treatment.Some diseases are heavily stigmatized – including mental health, HIV/AIDS, hepatitis and some skin conditions – leading people to restrict their participation in society, impairing their chances of living happy, healthy lives.However, to one extent or...
Source: EyeForPharma - July 17, 2018 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

In Search of Pharma ’s Moore’s Law
Artificial Intelligence (AI) has made great strides in the past five years. We are probably using an AI-based system without even realizing it in our daily lives today. There is a lot of active research going on in AI in both academia and in the pharma industry. Within pharma, several opportunities open up as we think of AI making an impactful difference; lead candidate identification, drug development, compound repurposing, clinical trials, post approval, commercial markets, etc. Let us look at one area closely, that of planning and conduct of clinical trials.Costs of bringing a drug to the market over the last three deca...
Source: EyeForPharma - July 5, 2018 Category: Pharmaceuticals Authors: Sagar Anisingaraju Source Type: news

The Highs and Lows of Healthcare
Every once in a while, I meet someone who I think should be the ‘patient-centric poster child’.This person is doing great work advancing their organization ’s efforts to create better outcomes for patients (and so better outcomes for their company and people). In the spirit of illuminating our path to patient-centricity, growing together faster than any of us can alone, this column is dedicated to sharing their stories, successes and challenges.Doug Noland, Head Patient Experience, Executive Director, Astellas US, shares why he is on a mission to create a culture of patient-centricity and loving it.Before...
Source: EyeForPharma - July 5, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

First, We Need To Talk: Mental Healthcare In The MENA Region
The Middle East and North Africa (MENA) face daunting challenges in managing a growing burden of mental illness, often in adverse conditions that can leave their imprint on generations to come.While the burden of mental-health conditions is above the global average in most MENA countries, the human resources, policies, funding and infrastructure to deal with these problems are sorely lacking.According to a recent study led by the Institute for Health Metrics and Evaluation (IHME), mental disorders excluding substance abuse accounted for 4.7% of all disability-adjusted life years (DALYs) in the World Health Organization &rs...
Source: EyeForPharma - July 5, 2018 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

Becoming the #1 Partner to Patient Groups
“We don’t partner with patient groups to have a good reputation,” says Amy Nicole Nayar, Head of Global Patient Relations at Abbvie. “If you want to partner with patient groups to improve your reputation, you will miss the mark.” An authentic intention to improve patient outcomes is the key factor to success.  We all want to be patient-centric, says Nayar. “There’s a reason why we all come to this industry,” she says.For her, it ’s personal – she grew up with a brother who had epilepsy and received an innovative treatment. Although it didn’t change...
Source: EyeForPharma - June 15, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Where Next For Digital Support Programs?
Is the pharma business model broken? How will pharma firms deliver true value and relevance in the years ahead? What is the step change required?These questions were at the back of my mind when S3 Connected Health and eyeforpharma were working on our joint white paper,Patient Support Programs: Now, Near, Next. We wanted to take the pulse of industry experts on their ‘beyond the pill’ strategy, so we spoke to 20+ senior leaders currently designing and implementing patient support programs (PSPs) from firms including Novartis, AstraZeneca, Sanofi and Takeda.All are mindful of the wider context; hugely expensive d...
Source: EyeForPharma - June 15, 2018 Category: Pharmaceuticals Authors: Jim O ' Donoghue Source Type: news

Data Analytics: The New Gold Standard In Drug Value
Conclusion The fundamental shift underway is in the use of data analytics as a strategic foundational layer, asking what insights are needed to assist in more informed decision making, driving data points to include during the development of new treatments.The following four elements are essential for drug developers to realize the benefits of this new approach: Put data analytics at the center of strategic thinking and augment conclusions with KOL input, rather than the other way around. Empower development around patient insights derived from carefully designed data-analytics. Focus on discovering patient value rath...
Source: EyeForPharma - May 30, 2018 Category: Pharmaceuticals Authors: Preeti Patel and Sophie Schmitz Source Type: news

know your customer
Channels: MultichannelPatients and MedicalImage: URL: https://goo.gl/R9FKZxExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - April 25, 2018 Category: Pharmaceuticals Authors: Andy Robertson Source Type: news

The rep of tomorrow today
Channels: MultichannelImage: URL: https://goo.gl/RztynaExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - April 25, 2018 Category: Pharmaceuticals Authors: Andy Robertson Source Type: news

Achieving Success in Emerging Markets
In developed countries, the quality of medicines is consistently good – regardless of whether a medicine is an original formulation or generic – due to long-standing and strict quality regulations. However, this is not always the case in emerging markets, where access to reliable, quality medicines has been inconsistent historically.The situation is changing, and many emerging markets are implementing stricter guidelines. In 2017, the World Health Organization said one-in-ten medicines in low-and middle-income countries were found to be substandard or falsified, an improvement on one-in-four in 2007.Beyond qual...
Source: EyeForPharma - April 16, 2018 Category: Pharmaceuticals Authors: Andrew Lane Source Type: news

Working Together Wins The Day
If the constant talk about collaboration reflects an awkward truth, it ’s that pharma’s silos too often silence the patient voice and stymie progress. Today, Jen Horonjeff was named this year's Patient Advocate for her efforts in breaking down these barriers — both in her personal and professional life — at eyeforpharma’s annual Philadelphia event.She praised the Patient Advocate award for shining a light on the value that comes from collaborating with patients to co-create solutions, and for recognizing the efforts that are happening outside of the industry.“It is such an honour to win ...
Source: EyeForPharma - April 11, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Patient Support Program Triumphs
A patient support program offering around the clock assistance to glioblastoma multiforme (GBM) patients undergoing an innovative therapy has been named the Most Valuable Patient Initiative award at eyeforpharma ’s annual awards ceremony in Philadelphia.   Reflecting on the win, Novocure said: “We are humbled to have helped so many patients and to be recognised for it by our peers who have made careers out of trying to help patients in the most need. The eyeforpharma awards are helping pharma to focus on its core constituent — the patient.”  In naming the PSP as the winner of the 2018...
Source: EyeForPharma - April 10, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Good Intentions, Bad Habits: Reforming Mental Healthcare In LatAm
The Latin America and Caribbean (LAC) region is a vast patchwork of countries, cultures and ethnicities with a total population of more than 645 million, ranging from 209 million-plus in Brazil to islands with fewer than 100,000 inhabitants.The diversity is also economic; recent years have seen marked improvements in income distribution and a burgeoning middle class, particularly in countries such as Argentina, Bolivia, Ecuador, Peru and Nicaragua. Yet, LAC remains the region with the highest levels of income inequality worldwide.All of this has a significant bearing on the state of mental health, where good intentions and...
Source: EyeForPharma - April 9, 2018 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

Helping Patients Learn Healthy Habits
What if we told you we could improve health outcomes for more than 50% of patients and save the US healthcare system up to $289bn a year?That ’s the averagecost of nonadherence to prescribed medications, or in layman ’s terms, not taking your meds. Fixing this epidemic could not only save billions of dollars but, with around 125,000 deaths a year in the US due to failure to follow doctor’s orders, it could save thousands of lives too.Better lifestyle decisions can solve many of our personal health problems; eating healthily, regular exercise, taking your pills, are all positive behaviors that contribute t...
Source: EyeForPharma - April 5, 2018 Category: Pharmaceuticals Authors: Steve Peretz and Meg Donchak Source Type: news

Rare Diseases: A New Purpose
The US National Institutes of Health describes drug repurposing as “studying drugs that are already approved to treat one disease or condition to see if they are safe and effective for treating other diseases”.The investment and time required to repurpose a drug is significantly less when compared to new drug discovery and could, therefore, translate into potentially lower prices and faster access to new treatments.Government incentives for rare diseases Historically, orphan drugs and their relatively small target populations have been a particularly risky endeavor for pharmaceutical companies. Considering tha...
Source: EyeForPharma - April 5, 2018 Category: Pharmaceuticals Authors: Preeti Patel and Sophie Schmitz Source Type: news

Out of the Shadows: Mental Health in Asia Pacific
Mental health has been a peripheral issue in emerging markets for a long time, despite the severe impact not only on those directly affected but also on families and carers, as well as on social cohesion and economic development.Fortunately, mental health is starting to get more attention but there is still a widespread tendency to stigmatize and discriminate against people suffering with a mental illness. They are often considered as dangerous and aggressive which in turn increases the social distance.Is there an opportunity for pharma to do more? In the first of a series of articles exploring mental health in emerging ma...
Source: EyeForPharma - February 14, 2018 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

Why Pharma Needs to Understand Population Health
It ’s no secret that healthcare is under growing pressure to reduce the cost of care while improving quality. Linkage of payment for healthcare to the cost and quality delivered – the idea behind value-based payment frameworks – is the driving force behind today’s rapidly changing healthcare la ndscape.Such linkage will likely be achieved using a population health model, where a provider contracts to deliver designated services to specific quality targets at an agreed-upon ‘all-in’ price. The arrangement makes the contracting provider financially accountable for cost over-runs and qualit...
Source: EyeForPharma - February 12, 2018 Category: Pharmaceuticals Authors: Rita Numerof Source Type: news

AstraZeneca: An Embarrassment Of Riches
2017 was a busy year for AstraZeneca. With 19 major new drug approvals in the US, Europe and Japan, many are looking to the company ’s rise in R&D productivity described by Mene Pangalos, head of its Innovative Medicines and Early Development unit,in a recent Reuters article as “less people, less sites and less money”.With so many launches, it was also a very busy year for Medical Affairs, says Mark Mallon, EVP, Global Product and Portfolio Strategy, Global Medical Affairs and Global Corporate Affairs.“2017 was unprecedented – one of the best company performances in the industry – bu...
Source: EyeForPharma - February 7, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Build It And They Will Come
In the award-winning 1989 movie,Field of Dreams, Kevin Costner hears a voice telling him to build a baseball field on his farm in Iowa. " If you build it, he will come, ” says the voice. Against the warnings of many, and with nothing but faith, he builds the field and (spoiler alert!) his dream comes true when he meets and plays ball with his hero, baseball legend Shoeless Joe Jackson.While the pharmaceutical industry is not well-known for such whimsical notions, for a sector rooted in science, it takes a lot on faith. We – the thousands whose jobs depend on it and the millions of patients worldwide &ndash...
Source: EyeForPharma - February 2, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

PSPs: Avoiding the Pitfalls, Part 2
The objective is to change people ’s behavior, and that means dealing with complex and context-driven human psychology.Over 17 years of experience of developing patient support programs, we have recognized five ingredients needed to change behavior. They are: Deep insight into how patients think, feel and behave Health psychology expertise to diagnose the problems and design solutions A map of possible therapy failure points to ensure appropriate interventions are in place A consistent approach from the insights, to design and delivery of the program The agility to respond to individual needs and change.The...
Source: EyeForPharma - January 18, 2018 Category: Pharmaceuticals Authors: Nagore Fernandez and Nareda Mills Source Type: news

Pharma's Tech Opportunity: Can we seize it?
Channels: MultichannelImage: URL: http://www.eyeforpharma.com/pa/webinar2/?partner=eyeforpharma-externalExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - January 17, 2018 Category: Pharmaceuticals Authors: Andy Robertson Source Type: news

Patients and Medical
(Source: EyeForPharma)
Source: EyeForPharma - January 12, 2018 Category: Pharmaceuticals Authors: Admin Source Type: news

Medical Under The Microscope
Having spent the majority of his career in academia, it is unsurprising that Juan Ochoa has brought scientific rigour and analysis to his role as Chief Medical Officer at Nestle Health Science. He focuses on commercialising concepts that originate in the laboratory by developing value propositions based on clinical and real-world evidence.The former trauma surgeon tells eyeforpharma that the value of a company and the solutions that they bring are ultimately determined by their capacityto solve unmet needs for the end consumer. According to Ochoa, there are several targets in healthcare – the patient, the physician, ...
Source: EyeForPharma - January 5, 2018 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

Medical Under The Microscope
Having spent the majority of his career in academia, it is unsurprising that Juan Ochoa has brought scientific rigour and analysis to his role as Chief Medical Officer at Nestle Health Science. He focuses on commercialising concepts that originate in the laboratory by developing value propositions based on clinical and real-world evidence.The former trauma surgeon tells eyeforpharma that the value of a company and the solutions that they bring are ultimately determined by their capacityto solve unmet needs for the end consumer. According to Ochoa, there are several targets in healthcare – the patient, the physician, ...
Source: EyeForPharma - January 5, 2018 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

Innovation, Sustainability, Prosperity: Japan ’s Healthcare Vision
In 2015, the Japanese government appointed an advisory panel of young experts to lay out its vision of healthcare in the country for 2035. This vision is a healthcare system that delivers unrivalled health outcomes, provides secure and responsive care for all in society, is sustainable, and contributes to prosperity in the nation and around the world.Yet, how achievable is this ideal, and how does the government plan to realize its vision? What is clear is that it will require a paradigm shift – a move from quantity to quality of care and from inputs to value, on care rather than cure, on autonomy over regulation, on...
Source: EyeForPharma - January 5, 2018 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

The Pharma Business Model: How to Avoid the Innovator's Dilemma
Healthcare is the largest sector in the world – around three times larger than banking – yet, in spite of the cutting-edge medical breakthroughs, it lags behind in other forms of innovation.Pharma continues to spend heavily on R&D (around $140bn a year), which results in 30-40 new drug approvals each year, a return on investment that is not as strong as one might expect for the investment. The industry is an example of a ‘business-as-we’ve-always-done-it’ approach. The experiences of other disrupted industries may be relevant to pharma, such as: Continuing ‘business as usual&r...
Source: EyeForPharma - January 4, 2018 Category: Pharmaceuticals Authors: Dr Andree Bates Source Type: news

The Pharma Business Model: How to Avoid the Innovators Dilemma
Healthcare is the largest sector in the world – around three times larger than banking – yet, in spite of the cutting-edge medical breakthroughs, it lags behind in other forms of innovation.Pharma continues to spend heavily on R&D (around $140bn a year), which results in 30-40 new drug approvals each year, a return on investment that is not as strong as one might expect for the investment. The industry is an example of a ‘business-as-we’ve-always-done-it’ approach. The experiences of other disrupted industries may be relevant to pharma, such as: Continuing ‘business as usual&r...
Source: EyeForPharma - January 4, 2018 Category: Pharmaceuticals Authors: Dr Andree Bates Source Type: news

Putting Medical Under The Microscope
Having spent the majority of his career in academia, it is unsurprising that Juan Ochoa has brought scientific rigour and analysis to his role as Chief Medical Officer at Nestle Health Science. He focuses on commercialising concepts that originate in the laboratory benches by developing value propositions based on clinical and real-world evidence.The former trauma surgeon tells eyeforpharma that the value of a company and the solutions that they bring are ultimately determined by their capacity to solve unmet needs for the end consumer. According to Ochoa, there are several targets in healthcare – the patient, the ph...
Source: EyeForPharma - January 3, 2018 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

Free Webinar: Lean Marketing Innovation for Generics
Channels: CommercialImage: URL: http://www.eyeforpharma.com/philadelphia/webinar2/?partner=efp-website&utm_source=efp%20website&utm_medium=event%20listing&utm_campaign=4894&utm_content=generics%20webinarExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - December 21, 2017 Category: Pharmaceuticals Authors: Andy Robertson Source Type: news

Carers: The Forgotten Heroes of Healthcare
In healthcare nowadays, we talk a lot about the patient journey – the entirety of a person's experience from first symptom to final treatment. Yet, it is easy to forget that the patient is rarely alone on this life trek.' Informal'carers are the forgotten heroes of every patient story – forgotten, most of all perhaps, by pharma. Until recently, caregivers have been relegated to the background; after all, it's the patient that takes a medicine, isn't it?The truth is that carers walk alongside the people they care for throughout the entire journey. They drive patients to appointments then sit with them in the wai...
Source: EyeForPharma - December 19, 2017 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

Carers: The Forgotten Heroes of Healthcare
In healthcare nowadays, we talk a lot about the patient journey – the entirety of a person's experience from first symptom to final treatment. Yet, it is easy to forget that the patient is rarely alone on this life trek.' Informal'carers are the forgotten heroes of every patient story – forgotten, most of all perhaps, by pharma. Until recently, caregivers have been relegated to the background; after all, it's the patient that takes a medicine, isn't it?The truth is that carers walk alongside the people they care for throughout the entire journey. They drive patients to appointments then sit with them in the wai...
Source: EyeForPharma - December 19, 2017 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

The Death Of The Brand
There once was a time when big brands could to an extent rest on their laurels, sleeping soundly with the knowledge that they held the monopoly on their respective markets. Then one day the big bad internet of ideas jostled its way onto the scene, bringing with it a proliferation of new products and plucky start-ups.Fast-forward to the present and the customer is now at the steering wheel, with multiple destinations in front of them and multiple means of getting there.Why will they come to you? To survive in this new marketplace, companies must be nimble and adaptive, listening attentively to the needs of its customers. Th...
Source: EyeForPharma - December 19, 2017 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

ePROs: Why We Should Be Mobile-First
Electronic patient-reported outcomes (ePROs) and in particular with Bring Your Own Device (BYOD) are increasingly being used to collect data directly from patients. The advantages include bigger, faster and more efficient trials, avoiding missing data on a questionnaire, time-stamped data and complex question branching.However, with people ’s attention spans shortening, there is a growing need to make surveys lean. With more and more surveys taken on mobile phones, if the survey is too long or badly designed participants will drop out.While there are established guidelines for measuringequivalence between electronic ...
Source: EyeForPharma - November 23, 2017 Category: Pharmaceuticals Authors: Keith Meadows Source Type: news

PSPs: Avoiding the Pitfalls
With the rise of specialty medicines, the staggering cost of non-adherence and the demand for value from all stakeholders, it ’s no surprise that patient support programs (PSPs) are becoming ‘cost of entry’ for some products.However, it ’s not enough to simply bolt on a one-size-fits-all support service around a new medicine; the bar is high, and the ambition is to deliver a truly differentiated service with measurable results.In a recent blog post, we identifiedfive big pitfalls to avoid to deliver successful PSPs. In this article, we focus on the first two, asking what steps companies need to take...
Source: EyeForPharma - November 7, 2017 Category: Pharmaceuticals Authors: Nagore Fernandez and Nareda Mills Source Type: news

Artificial Intelligence: Friend Or Foe?
It is safe to say that popular fiction has not been too kind to artificial intelligence. Its origins can be seen in Mary Shelley ’s time-honoured parable about the creator who is destroyed by his creation.Countless sci-fi depictions suggest AI has become the modern-day iteration, the ultimate metaphor for mankind ’s self-destructive power (think Skynet’s killing machines). These depictions may capture our imagination, but do they match reality? Is AI technology maligned and misunderstood?  The Oxford Dictionary defines artificial intelligence as: “The theory and development of computer sys...
Source: EyeForPharma - November 6, 2017 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Living with NASH: An Unexpected Diagnosis
As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it ’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol.Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD), where fat accumulates in the liver. It is most commonly associated with obesity, insulin resistance, metabolic syndrome and/or genetic polymorphisms, and is aggravated by inflammation and fibrosis.  First identified in the 1980s, its ...
Source: EyeForPharma - November 3, 2017 Category: Pharmaceuticals Authors: Mariel Metcalfe Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: Patients and MedicalTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: CommercialTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Don ’t Just Digitize. Embrace Digitalization
In June, the Techtour Healthtech Summit returned to Lausanne with an overarching theme of the convergence of medtech and digital health, and the search for a successful digital business model.Although there were two tracks – medtech and digital health – there were digital health companies in the medtech stream and lab companies in the digital health stream that felt very much like medtech.One way to tease apart this convergence and to ask how future business models may evolve is to look at whether companies simplydigitizeanalog processes or fullydigitalize.The digitization of an analog process aims to deliver e...
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Douglas Haggstrom Source Type: news

Don ’t Just Digitize: Embrace Digitalization
In June, the Techtour Healthtech Summit returned to Lausanne with an overarching theme of the convergence of medtech and digital health, and the search for a successful digital business model.Although there were two tracks – medtech and digital health – there were digital health companies in the medtech stream and lab companies in the digital health stream that felt very much like medtech.One way to tease apart this convergence and to ask how future business models may evolve is to look at whether companies simplydigitizeanalog processes or fullydigitalize.The digitization of an analog process aims to deliver e...
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Douglas Haggstrom Source Type: news

MSLs: The Superheroes of Pharma?
This article appeared in the most recent edition of our specialist publication,  Trends in Medical Affairs.Click to download a copy.  Related Content: Navigating The New LandscapeBest of Both WorldsPrimary Event: Medical Affairs Europe 2018Pr écis: MSLs are pharma ’s elite, with the knowledge and interpersonal skills to engage and collaborate with customers. But is pharma asking too much of its scientific superheroes?Premium`: Freemium`: Channels: Patients and MedicalTags: medical affairs (Source: EyeForPharma)
Source: EyeForPharma - October 25, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

MSLs: The Superheroes of Pharma?
The Medical Science Liaison (MSL) has come a long way in a short time. While pharma never stands still for long, the need for scientifically credible partners to help customers understand the growing complexity of new medicines and navigate the choppy waters of real-world evidence and health outcomes, has seen the MSL come to the fore in ways few might have imagined.While the core competencies of the MSL remain unchanged, new capabilities will be needed – both for MSLs and MSL leaders – to meet the demands of the changing roles. But what does the modern MSL look like and what skills will they need now and in th...
Source: EyeForPharma - October 25, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

The Digital Disruption
“We are now marketers in a data-driven world,” says Steve Mason, Multichannel and Marketing Cloud Expert at Sales Force. His epochal address, aimed squarely at the pharma industry during eyeforpharma’s Marketing and Customer Innovation event last year, could not have been clearer: get digitall y savvy or get left behind.It ’s an unassailable argument. Strides in digital innovation have redefined the ways we organise our time and space. The proliferation of digital channels - combined with the free flow of information readily available - has made the customer experience more integrated and personalis...
Source: EyeForPharma - October 23, 2017 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news